Aging Populations And Gene Therapies Will Drive Precision Medicine
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 25 Analysts
Published
13 Jul 25
Updated
15 Aug 25
AnalystHighTarget's Fair Value
US$666.61
25.3% undervalued intrinsic discount15 Aug
US$498.29
1Y
-18.9%7D
4.4%